EOS Conference Highlights Urgent Need For Accelerating AI Integration In Cancer Care

The 6th Annual Emirates Oncology Society (EOS) Conference recently wrapped up in Dubai, attracting over 700 participants, including top medical and research professionals from the UAE and beyond. The event's final day focused on advanced medical technologies and innovations that are transforming cancer treatment both regionally and globally.

Participants explored several advanced topics, with a particular focus on molecular diagnostics using circulating tumor DNA (ctDNA). This technology offers new possibilities for early relapse detection and guiding treatment in colorectal cancers. Experts also highlighted the Hepatic Arterial Infusion Pump (HAIP), which represents a significant advancement in liver cancer care by delivering chemotherapy directly to the hepatic artery, thereby improving local disease control.

The conference also delved into the latest developments in immunotherapies and targeted treatments, showing promising outcomes for advanced liver cancers. Discussions revealed a "medical revolution" in gynecologic oncology through new targeted therapies. Advances in precision radiotherapy and minimally invasive surgery using SBRT and proton therapy were also emphasized.

Experts stressed the importance of artificial intelligence and digital analytics in enhancing diagnostic accuracy, predicting patient responses, and improving cancer data management. These technologies are seen as crucial for advancing cancer care by providing more precise and effective treatment options.

The conference concluded with strategic recommendations aimed at improving cancer care. These included accelerating the integration of digital technology and AI into diagnostics, expanding genetic and molecular testing to advance precision medicine, adopting non-invasive early detection tools like liquid biopsy, and scaling up innovative techniques such as HAIP by training regional centers.

Strategic Recommendations for Future Care

Additional recommendations focused on investing in local clinical research to reflect unique patient characteristics, strengthening partnerships with global companies to bring cutting-edge treatments to the UAE, and reinforcing the UAE’s role as a regional hub for oncology innovation.

Professor Humaid Bin Harmal Al Shamsi, President of the Emirates Oncology Society, stated: "We are proud of the rich outcomes achieved during this conference, which serve as a roadmap for the future of cancer care in the region. The recommendations highlight the urgent need to accelerate the adoption of innovative medical technologies and artificial intelligence, in line with the UAE’s vision to foster medical innovation and provide the best possible care for patients. We firmly believe that combining science, innovation, and digital technology is the best path to transforming cancer care for a better future."

These insights from the conference underscore an urgent call to action for integrating innovative medical technologies into cancer care. By doing so, they aim to align with UAE's vision of fostering medical innovation while ensuring optimal patient care.

With inputs from WAM